Healthcare

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target…

4 days ago

Ngram Releases Groundbreaking AI Dataset to Revolutionize Medical Information Access for Healthcare Professionals

New open-source dataset aims to help pharmaceutical companies provide faster, more accurate responses to healthcare provider inquiries about drugsSAN FRANCISCO,…

4 days ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy…

4 days ago

Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024

Live Conference Call and Webcast at 8:30 a.m. ETPRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX),…

4 days ago

 Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

Live webcast presentation on Wednesday, March 20th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) --…

4 days ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced…

4 days ago

DiagnaMed Announces BRAIN AGE® Trademark Registration Approved by CIPO

BRAIN AGE® solution is part of the CERVAI™ Brain Health AI Platform CERVAI™ Brain Health TORONTO, March 20, 2024 (GLOBE…

4 days ago

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6…

4 days ago

Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results – Record Guidance for 2024 – Doubles Dividend to 2.00 per Share

Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval…

4 days ago

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in…

4 days ago